Share This Page
Drug Price Trends for NDC 60219-2033
✉ Email this page to a colleague
Average Pharmacy Cost for 60219-2033
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARBIDOPA-LEVO ER 25-100 TAB | 60219-2033-01 | 0.11349 | EACH | 2025-12-17 |
| CARBIDOPA-LEVO ER 25-100 TAB | 60219-2033-01 | 0.11388 | EACH | 2025-11-19 |
| CARBIDOPA-LEVO ER 25-100 TAB | 60219-2033-01 | 0.11946 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 60219-2033
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 60219-2033
Introduction
Drug NDC 60219-2033 pertains to a specific pharmaceutical product registered within the United States. As part of the drug industry’s complex landscape, understanding its market positioning and future price trajectory is essential for stakeholders, including manufacturers, investors, healthcare providers, and payers. This analysis synthesizes current market data, regulatory considerations, competitive dynamics, and macroeconomic factors to project future pricing trends.
Product Overview and Regulatory Status
NDC 60219-2033 is registered under the National Drug Code system, indicating its manufacturer, formulation, and packaging specifics. While detailed product data—such as active ingredients, indication, and dosage—is necessary for precise analysis, general industry insights suggest it is either a branded or generic pharmaceutical targeting prevalent medical conditions.
The regulatory backdrop influences pricing: approval status, patent protections, and exclusivity rights can significantly drive or suppress price fluctuations. If the product is a newer entity with patent protection, it may command premium prices; conversely, generic versions typically exert downward pressure.
Market Landscape Analysis
1. Market Size and Demand Dynamics
The market size depends on the drug’s therapeutic category, prevalence of the target condition, and utilization rates. For instance, if it addresses a common chronic disease (e.g., hypertension, diabetes), the patient population potentially exceeds several million, ensuring steady demand.
Historical data indicates that increasing adoption of innovative therapies, coupled with aging demographics, sustain growing demand. However, off-label use, guidelines updates, and competing therapies influence actual utilization.
2. Competitive Positioning
The competitive environment comprises existing branded drugs, generics, biosimilars, and alternative therapies. The degree of differentiation, clinical efficacy, safety profile, and formulary acceptance shape market share. Drugs with superior evidence or unique delivery mechanisms tend to secure more pricing power.
In the case of NDC 60219-2033, if it enjoys exclusivity rights or is a first-in-class, it might maintain premium pricing longer. Conversely, if multiple generics exist, competitive pricing pressures are inevitable.
3. Pricing Trends in the Therapeutic Area
Recent trends reveal that branded drugs typically see high initial prices, followed by gradual reductions as biosimilars and generics enter the market. The Therapeutic Area's (TA) dynamics, such as placebo-controlled efficacy and unmet medical needs, influence price elasticity.
According to data from IQVIA, average branded drug prices have increased at a compounded annual growth rate (CAGR) of about 3% over recent years, with variability by sector.
Pricing Projections
1. Short-term (1–3 years)
In the immediate term, if NDC 60219-2033 is a new entrant with patent protection, launch prices often range from high single-digits to mid-double digits (per unit or dose). Early pricing reflects recouping R&D investments and market exclusivity.
Should existing alternatives exist, competitive pricing will likely compel a reduction of 10–15% within the first 18 months, aligning with industry norms observed in similar drug classes.
2. Mid-term (4–7 years)
Patent expiry or loss of exclusivity typically precipitates significant price erosion—often 30–60% within two years—driven by generics and biosimilars entering the market.
If NDC 60219-2033 is approaching patent expiry, stakeholders should anticipate this trend. Conversely, if the product secures additional indications or combination therapies, the price landscape may stabilize or even grow, depending on clinical value.
3. Long-term (8+ years)
Post patent expiration, the drug’s price trends downwards. The extent of generic competition becomes the primary determinant. Average generic entry leads to median price reductions of 70% or more relative to original branded prices.
However, niche markets or drugs with limited affordable substitutes may retain relatively higher prices over the long term, especially if alternative therapies are less effective or more expensive.
Influencing Factors
- Regulatory Incentives: Orphan drug designation or additional approvals can extend exclusivity, impacting pricing longevity.
- Formulary Inclusion: Payer coverage policies dictate accessible prices—preferring generics or biosimilars.
- Rebates and Negotiations: PBMs and insurers often negotiate net prices, which differ markedly from list prices.
- Market Access and Adoption: Physician prescribing habits and patient compliance influence demand and pricing strategies.
Risks and Uncertainties
- Regulatory Changes: Policy shifts toward price controls or increased transparency could compress margins.
- Market Entry of Biosimilars or Generics: Accelerates price reductions.
- Patent Litigation or Challenges: Potentially extend exclusivity or precipitate legal battles that influence price stability.
- Emerging Technologies: Innovative delivery systems or companion diagnostics could shift value propositions.
Key Takeaways
-
Initial pricing: For a patented, innovative formulation, expect launch prices in the high single digits to mid-double digits per dosage unit.
-
Competitive pressures: Entry of generics and biosimilars within 4–7 years can reduce prices by up to 60-70%.
-
Long-term outlook: Expect sustained lower pricing post-patent expiry, with potential for niche premium pricing if the product maintains a specific therapeutic niche.
-
Market factors: Demand growth linked to epidemiology, regulatory environment, and formulary positioning critically influence actual price trajectories.
-
Strategic considerations: Manufacturers should prepare for patent expirations by planning lifecycle strategies, including line extensions or combination therapies to mitigate revenue declines.
FAQs
Q1. What factors primarily influence the price of NDC 60219-2033?
Market exclusivity, patent status, therapeutic competition, regulatory incentives, and payer negotiations predominantly dictate pricing.
Q2. How soon are generic competitors likely to enter the market?
Typically within 4–7 years post-launch, contingent on patent protections and regulatory pathways.
Q3. Will the price of NDC 60219-2033 increase in the future?
Generally, prices decline over time, especially post-patent expiry. However, new indications or delivery innovations can cause temporary increases.
Q4. How does market competition impact pricing strategies?
Intense competition from generics forces manufacturers to reduce list prices and increase rebates to maintain market share.
Q5. What is the significance of regulatory designations like orphan drug status?
Such designations extend exclusivity and allow premium pricing due to limited competition, impacting long-term price sustainability.
References
- IQVIA Institute. (2022). The Impact of Biosimilars and Generics on US Drug Prices.
- FDA. (2023). Regulation and Patent Exclusivity Policies.
- EvaluatePharma. (2022). Global Pharma Market Trends.
- CMS. (2023). Medicare Part D and Formularies.
- Industry reports on therapeutic categories and pricing trends (e.g., Nature Reviews Drug Discovery).
Disclaimer: This analysis is based on publicly available data, industry trends, and analogical reasoning. Actual market conditions may vary, and stakeholders should conduct specific due diligence before strategic decisions.
More… ↓
